Non-GIST Soft Tissue Sarcoma: Biology and Basics of Targeted Therapy

Sarcoma

Simplest Conceptual Level

Mutational Heterogeneity and the Search for New Cancer-Associated Genes

Mutational Heterogeneity and the Search for New Cancer-Associated Genes

Considerations When Selecting Therapy for Sarcoma

Chemotherapy Plus Ifosfamide in STS

Advanced Disease

What Guides Our Practice?

Doxorubicin-Based Chemotherapy for Soft Tissue Sarcoma

Major Non-GIST Sarcoma Studies Reported Since 2011

Doxorubicin vs Intensified Doxorubicin Plus Ifosfamide for Advanced STS: Phase 3

Doxorubicin vs Intensified Doxorubicin Plus Ifosfamide: Post-Protocol Treatment

First-Line Gemcitabine + Docetaxel vs Doxorubicin in Unresectable/Metastatic STS: GeDDiS

GeDDiS: PFS Results

GeDDiS: OS Results

GeDDiS: Subgroup Analyses

Pazopanib for Treatment of Metastatic STS: Phase 3 PALETTE Study

PDGFR

PDGFRα Is an Active Mediator of Rapamycin-Induced Akt Activation

Olaratumab in Advanced STS: Phase 1b/2 Study

Statistical Assumptions (Phase 2)

Overall Tumor Response (ITT; Phase 2)

PFS and OS in the ITT Population (Phase 2)

Liposarcoma

Well Differentiated/Dedifferentiated Liposarcoma

Delayed Response to Treatment

Palbociclib in Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma: Phase 2

PVNS: TGCT

PVNS and GCT-TS: High Morbidity

PVNS/TGCT

Imatinib Mesylate for the Treatment of Locally Advanced and/or Metastatic TGCT/PVNS

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)